1. Pink Sheet
  2. >>Agency Leadership

Oz’s Magic: US CMS Administrator Pick Praises Staff, Unlike Other Trump Health Care Nominees

 
• By Michael McCaughan

US CMS Administrator nominee Mehmet Oz promises to inspire the agency he is set to lead and seems likely to succeed compared to other Trump Administration nominees.

CMS Administrator nominee Mehmet Oz appeared to impress Senators from both parties during his confirmation hearing. (Screenshot of CSPAN Broadcast)
Key Takeaways
  • CMS Administrator nominee Mehmet Oz’s praise for CMS staff during his confirmation hearing stood out compared to the Trump Administration’s other health care leadership choices, in part because it was not in his written statement.
  • Oz said he intended to build morale and excitement within the agency.
  • He also made clear that he would be running CMS if confirmed, not the Department of Government Efficiency.

Simple words of praise from a nominee for the agency he was chosen to lead seem almost radical, which says a lot about the early weeks of President Donald Trump’s...

In the opening statement at his 14 March Senate confirmation hearing, US Centers for Medicare and Medicaid Services Administrator nominee Mehmet Oz said while discussing his...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Agency Leadership

US FDA Punts On New COVID-19 Framework’s Impact On Fall Shots

 
• By Sarah Karlin-Smith

The FDA’s advisors split on whether to update COVID-19 vaccines for the fall. The agency refused to discuss the impact of the new vaccine framework on impact availability.

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

Legal, Process Problems May Plague New US FDA COVID-19 Vaccine Policy

 
• By Sarah Karlin-Smith

The FDA may have violated laws and regulations along with many norms in how it released its planned changes for COVID-19 vaccine approvals.

Observational, Retrospective Trials Could Retest Vaccines, HHS’ Kennedy Says

 
• By Derrick Gingery

The Health and Human Services secretary told a Senate appropriations subcommittee that placebo-controlled trials may not be necessary to ensure vaccine safety as the FDA released a framework requiring them for COVID-19 vaccines.

More from Medicaid

Dr. Oz Takes Over CMS Amid Major Transformation Of Medicare Part D

 
• By Cathy Kelly

As CMS administrator, Mehmet Oz will oversee the second cycle of Medicare drug price negotiations and Part D redesign issues, but will have experienced deputies to help.

Dramatic HHS Layoffs A Response To ‘Existential Crisis,’ Kennedy Advisor Argues

 
• By Cathy Kelly

Calley Means defended reductions in force at the Health and Human Services Department that shocked and outraged federal workers and stakeholders.

Newest HHS Staff Cuts Could Stymie CMS Health Plan Oversight

 
• By Leslie Small

A former CMS manager worries casework and other necessary functions could suffer as a result of the 300 staff cuts at the agency that are part of a massive HHS restructuring.